Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.
Mitka
Mike
M
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000401:mortality; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone